Yahoo! Finance: OCLS News

Latest Financial News for Oculus Innovative Sciences, Inc

• Oculus Innovative Sciences Announces Vetericyn Wound Spray for Animals to be Distributed in over 1,000 PetSmart Stores (Business Wire)

  (Thu, 4 Dec 2008 13:08:00 Etc/GMT)

  PETALUMA, Calif.----Oculus Innovative Sciences, Inc. , a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to treat infections in chronic and acute wounds, announced today that the company’s Vetericyn™ Wound Spray for animals will become available in all North American PetSmart stores beginning mid-February 2009.

• Oculus Innovative Sciences Announces Agreement with Bayer Taiwan Co. Ltd. for Development of Microcyn® Technology Use in Taiwanese Animal Market (Business Wire)

  (Tue, 2 Dec 2008 13:08:00 Etc/GMT)

  PETALUMA, Calif.----Oculus Innovative Sciences, Inc. , a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to treat infections in chronic and acute wounds, announced today an agreement with Bayer Taiwan Co.

• Oculus Innovative Sciences Receives NASDAQ Notification (Business Wire)

  (Wed, 26 Nov 2008 22:00:00 Etc/GMT)

• OCULUS INNOVATIVE SCIENCES, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Ru (EDGAR Online)

  (Wed, 26 Nov 2008 21:52:42 Etc/GMT)

• OCULUS INNOVATIVE SCIENCES, INC. Financials (EDGAR Online Financials)

  (Thu, 20 Nov 2008 14:04:36 Etc/GMT)

• OCULUS INNOVATIVE SCIENCES, INC. Files SEC form 10-Q, Quarterly Report (EDGAR Online)

  (Thu, 13 Nov 2008 21:57:50 Etc/GMT)

• Oculus Innovative Sciences downgraded by Rodman & Renshaw (Briefing.com)

  (Fri, 7 Nov 2008 14:26:36 Etc/GMT)

• OCULUS INNOVATIVE SCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Stateme (EDGAR Online)

  (Thu, 6 Nov 2008 21:14:23 Etc/GMT)

• Oculus Innovative Sciences Reports Record Second Quarter Product Revenue Up 81% (Business Wire)

  (Thu, 6 Nov 2008 21:05:00 Etc/GMT)

  PETALUMA, Calif.----Oculus Innovative Sciences, Inc. today announced financial and operating results for the second quarter of fiscal year 2009, ended September 30, 2008. During the quarter the company increased product revenue sharply while reducing future operating expenses by $1.7 million to $2.0 million per quarter, which will be fully reflected in the company’s financial results beginning with the fourth quarter of fiscal 2009.

• Q2 2008 OCULUS INNOVATIVE SCIENCES INC Earnings Release - After Market Close (CCBN)

  (Thu, 6 Nov 2008 12:07:13 Etc/GMT)

Yahoo! Finance: OCLS Financial Blogs

Latest Financial Financial Blogs for Oculus Innovative Sciences, Inc

MSN Money News - OCLS

News about Oculus Innovative Sciences Inc

• Oculus Innovative Sciences Announces Agreement wi

  (Tuesday, December 02, 2008 8:08 AM)

  Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is

• Oculus Innovative Sciences Receives NASDAQ Notifi

  (Wednesday, November 26, 2008 5:00 PM)

  Oculus Innovative Sciences, Inc. (NASDAQ: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is

• Oculus Innovative Sciences Reports Record Second

  (Thursday, November 06, 2008 4:05 PM)

  Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) today announced financial and operating results for the second quarter of fiscal year 2009, ended September 30, 2008. During the quarter the company

• Oculus Innovative Sciences to Present at the Rodm

  (Tuesday, November 04, 2008 8:08 AM)

  Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, today announced

• Oculus Innovative Sciences Announces Fiscal Secon

  (Thursday, October 30, 2008 8:08 AM)

  Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, today

• Oculus Innovative Sciences Introduces Microcyn(R)

  (Wednesday, October 29, 2008 8:08 AM)

  Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) today announced that its Microcyn® Wound Care OTC, a non-irritating, pH-balanced wound cleanser, is now available over the counter in the United

• Oculus Innovative Sciences Launches Microcyn(R) W

  (Wednesday, October 22, 2008 8:08 AM)

  Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) today announced that it has launched its Microcyn Wound Care product into the U.S. podiatry market. The product, which has received three FDA 510(k)

OCLS - News and Analysis from Seeking Alpha

'OCLS' Tag RSS Syndication from SeekingAlpha.com

• China Biopharma Week in Review: Broad Views, Individual Companies

  (Sun, 14 Sep 2008 11:27:22 -0400)

  ChinaBio Today submits:

  In ChinaBio Today over the past five days, we featured three broad overviews of the China biomedical world, each sourced from an outside publication. The news these articles imparted may seem familiar to our regular readers, who are very aware of the transformation taking place in China biopharma. For the ChinaBio Today audience, the surprise may have been that the rest of the world still needs to be told.
  
  Two of these “outside” stories came out of the BioBay Investor Forum 2008,...

• Oculus Launches Wound Treatment Product in China

  (Sun, 14 Sep 2008 11:17:32 -0400)

  ChinaBio Today submits:

  Oculus Innovative Sciences (OCLS) is launching its Dermacyn wound treatment product in China by sending samples of the product to hospitals in ten China provinces. Sinopharm, the company in charge of China distribution of the product, also featured Dermacyn at a recent trade show, the New Drugs China Expo sponsored by Health Tech Forum 2008. The product was approved by the SFDA in March of this year to treat acute and chronic wounds including ulcers, cuts, contusions and burns.
  
  China is ahead...

• China Biotech in Review: A Week of Collaborations

  (Sun, 29 Jun 2008 10:09:14 -0400)

  ChinaBio Today submits:

  Last week witnessed the formation of an unusually high number of partnerships between biomedical companies, one of them China-based, the other(s) not. That should come as no particular surprise to readers of ChinaBio Today. Given the strong lure of participating in the China biopharma scene, ex-China companies are finding ways to participate in the advantages the country offers.
  
  Perhaps the most unexpected announcement last week came when WuXi PharmaTech (NYSE: WX) announced it had signed a Memorandum of Understanding with Covance (NYSE: CVD),...

• Oculus to Use Bayer for Approval of Wound Treatment in Animals

  (Wed, 25 Jun 2008 04:55:13 -0400)

  ChinaBio Today submits:

  Oculus Innovative Sciences, Inc. (NSDQ: OCLS) has engaged Bayer (Sichuan) to obtain approval for the use of its Microcyn wound healing/anti-infective product in pets and livestock.
  
  Bayer AG (BYERF.PK) of Germany formed Bayer (Sichuan) as a 70-30 joint venture with a local China company. The JV, which was established in 1997, produces animal health products from its Chendu factory.

  
  Complete Story »

• Oculus Innovative Sciences, Inc. F4Q08 (Qtr End 03/31/08) Earnings Call Transcript

  (Wed, 11 Jun 2008 22:10:27 -0400)

  Oculus Innovative Sciences, Inc. (OCLS)

  Q4 2008 Earnings Call

  
  Complete Story »

• Following the China Biopharma Beat

  (Sun, 25 May 2008 09:42:01 -0400)

  ChinaBio Today submits:

  Closing deals, winning drug approvals, receiving patents, announcing financial results, marketing drugs ? these are the markers of progress in a biopharma enterprise, and each was in evidence last week in the world of China biopharma.

  China Yongxin Pharmaceuticals Inc. (CYXN.OB), for example, announced that it has completed its previously announced reverse merger with Nutradyne Group, Inc. (see story). To celebrate the event and announce itself to the world, the company has changed the name and ticker symbol of the enterprise, broadcasting the changed business of the venture. In the...

• Oculus Devises China Marketing Plan for Wound Healing Product

  (Tue, 20 May 2008 02:47:15 -0400)

  ChinaBio Today submits:

  Oculus Innovative Sciences (NSDQ: OCLS) of Petaluma, CA has firmed up a plan for commercializing its Microcyn products in China, following SFDA approval two months ago. Oculus? China distribution partner, China Bao Tai, will distribute samples of Microcyn to key opinion leaders, asking them to test the clinical effect of the product by conducting post-approval trials. The data will be used to help secure reimbursement from insurance institutions.

  In China, Microcyn was approved for use in healing acute and chronic wounds, including ulcers, cuts, contusions and burns. This is a more comprehensive...

• Downturn in China Biotech Stocks Shows No Impact on Activity

  (Mon, 07 Apr 2008 07:53:22 -0400)

  ChinaBio Today submits:

  With the first quarter of 2008 officially history, the news for US-listed China biomedical companies was not good: a loss of 27% in the ChinaBio Index (see story). That put the CBI in between the benign loss (relatively speaking) of 14% for Nasdaq-listed stocks and a more major decline of 34% for the Shanghai Composite. As one of old stock market bromides says, stocks will do what they will do. But the downturn in stock prices hasn?t seemed to have much effect on China?s biomedical enterprises, which produced a heavier than usual...

• Oculus Receives SFDA Approval for Wound Treatment

  (Tue, 01 Apr 2008 04:00:31 -0400)

  ChinaBio Today submits:

  Oculus Innovative Sciences (OCLS) has received an approval from the SFDA of its Microcyn Technology for treatment of several acute and chronic wounds including ulcers, cuts, contusions and burns. Microcyn is a super-oxygenated form of water that is not toxic, but highly effective against bacteria, viruses, mold and spores. Microcyn combines its anti-infective properties with the ability to promote wound healing.

  In China, Oculus completed two clinical trials of the treatment in December, 2007, showing that it accelerated the healing of wounds in burns...

• Oculus Innovative Sciences IPO Analysis: Six Month Review

  (Mon, 13 Aug 2007 04:29:09 -0400)

  Oculus Innovative Sciences, Inc. (OCLS) is a recent IPO that is developing a product for the treatment of chronic wounds, Microcyn, which they call ?stable super-oxidized water.?

  · The active chemicals in Microcyn are hypochlorous acid and sodium hypochlorite, commonly available disinfectants found in household bleach, swimming pools and tap water.

  · It appears that a solution chemically indistinguishable from Microcyn could be made by diluting bleach in normal saline solution and adjusting the pH to 7.5.

  
  Complete Story »

Investor Clicks Financial Advertising

News for Oculus Innovative Sciences, Inc. - Google Finance

News for Oculus Innovative Sciences, Inc. - Google Finance

• Oculus sells Vetericyn in Taiwan, US

  (Thu, 04 Dec 2008 20:52:01 GMT)
  Oculus sells Vetericyn in Taiwan, US
  Santa Rosa Press Democrat - 3 hours ago

  BY LORALEE STEVENS PETALUMA, Dec. 4, 2008 -- Oculus Innovative Sciences Inc. (Nasdaq: OCLS) announced that Bayer Taiwan Co. Ltd. will develop the Microcyn-based animal wound care product Vetericyn ...

• Oculus Innovative Sciences Announces Vetericynâ?¢ Wound Spray for Animals to be Distributed in over 1,000 PetSmart Stores

  (Thu, 04 Dec 2008 15:12:01 GMT)
  Oculus Innovative Sciences Announces Vetericynâ?¢ Wound Spray for Animals to be Distributed in over 1,000 PetSmart Stores
  PR-Inside.com (Pressemitteilung) - 8 hours ago

  www.oculusis.com - Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology ...

  Oculus Innovative Sciences Announces Vetericyn(TM) Wound Spray for Animals to be Distributed in over 1,000 PetSmart Stores - Trading Markets (press release)
  Oculus Innovative Sciences Announces Vetericyn? Wound Spray for Animals to be Distributed in over 1,000 PetSmart Stores - International Business Times
  

• OCLS: Development Agreement w/Bayer Taiwan for Microcyn(R) Technology

  (Tue, 02 Dec 2008 13:57:33 GMT)
  OCLS: Development Agreement w/Bayer Taiwan for Microcyn(R) Technology
  Trading Markets (press release) - Dec 2, 2008

  Oculus Innovative Sciences, Inc. (OCLS) announced an agreement with Bayer Taiwan Co. Ltd. for development of the Microcyn(R) Technology for use in the Taiwanese animal market. As part of the ...

• Oculus Innovative Sciences Receives NASDAQ Notification

  (Wed, 26 Nov 2008 22:06:18 GMT)
  Oculus Innovative Sciences Receives NASDAQ Notification
  PR-Inside.com (Pressemitteilung) - Nov 26, 2008

  www.oculusis.com - Oculus Innovative Sciences, Inc. (NASDAQ: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology ...

  Oculus Innovative Sciences receives notification from NASDAQ regarding stockholders' equity - Trading Markets (press release)
  

• OCLS: To Present At Rodman & Renshaw Investment Conference @ 11:10 ET [delayed]

  (Tue, 11 Nov 2008 14:58:48 GMT)
  OCLS: To Present At Rodman & Renshaw Investment Conference @ 11:10 ET [delayed]
  Trading Markets (press release) - Nov 11, 2008

  Ridgeland, MS, NOV 11, 2008 (EventX/Knobias.com via COMTEX) -- OCLS | Quote | Chart | News | PowerRating -- Company representatives of Oculus Innovative Sciences Inc (NasdaqNM: OCLS | Quote ...

• Oculus Innovative Sciences to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on

  (Sat, 08 Nov 2008 02:05:31 GMT)
  Oculus Innovative Sciences to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on
  PR-Inside.com (Pressemitteilung) - Nov 8, 2008

  www.oculusis.com - Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn(R) Technology ...

• Sales up but losses mount for Oculus

  (Fri, 07 Nov 2008 14:11:33 GMT)
  Sales up but losses mount for Oculus
  Santa Rosa Press Democrat - Nov 7, 2008

  Oculus Innovative Sciences increased sales of its infection-fighting solutions last quarter but also widened its losses. The Petaluma biotech startup posted a $6.9 million loss Thursday for its ...

• Oculus Innovative Sciences Reports Record Second Quarter Product Revenue Up 81%

  (Thu, 06 Nov 2008 21:35:38 GMT)
  Oculus Innovative Sciences Reports Record Second Quarter Product Revenue Up 81%
  Ad-Hoc-News (Pressemitteilung) - Nov 6, 2008

  Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) today announced financial and operating results for the second quarter of fiscal year 2009, ended September 30, 2008. During the quarter the company ...

• The News in Brief

  (Mon, 03 Nov 2008 22:11:21 GMT)
  The News in Brief
  Santa Rosa Press Democrat - Nov 3, 2008

  PETALUMA ? Oculus Innovative Sciences Inc. (Nasdaq: OCLS) will sell its Microcyn Wound Care OTC product to consumers. Microcyn Wound Care OTC has been cleared by the FDA for moistening absorbent ...

• Microcyn Wound Care OTC launched

  (Thu, 30 Oct 2008 15:45:20 GMT)
  Microcyn Wound Care OTC launched
  Prescribing Reference - Oct 30, 2008

  Microcyn Wound Care OTC (oxychlorine topical cleanser, from Oculus Innovative Sciences) is now available without a prescription for moistening absorbent wound dressings and cleaning minor cuts ...

MarketWatch.com - All MarketWatch News - OCLS

MarketWatch, a leading publisher of business and financial news, offers users up-to-the minute news, investment tools, and subscription products.

• IPO Report: Fortress, CineMedia lead batch of 12 IPOs set for this week

  (Mon, 05 Feb 2007 10:50:00 -0500)

  NEW YORK (MarketWatch) - Fortress Investment Group and National CineMedia mark the richest in a fusillade of up to 12 initial public offerings on the calendar this week as the first big batch of 2007 IPOs attempt to tap into the bull market on Wall Street.

• Earnings Watch: Updates, advisories and surprises

  (Fri, 26 Jan 2007 08:31:09 -0500)

  A roundup of the latest corporate earnings reports and what companies are saying about future quarters.

• IPO Report: Mereulo Maddox's shares rise in debut after IPO pricing cut

  (Thu, 25 Jan 2007 04:28:00 -0500)

  NEW YORK (MarketWatch) -- Meruelo Maddox Properties Inc.'s shares rose in their stock-market debut Thursday, but only after the real-estate developer cut their offering price in the face of jitters in the overall sector.

• Oculus Innovative IPO trades at $7.90

  (Thu, 25 Jan 2007 11:28:18 -0500)

• Oculus Innovative IPO opens at $7.75, below $8 price

  (Thu, 25 Jan 2007 11:28:00 -0500)

• Oculus Innovative Sciences IPO debuts

  (Thu, 25 Jan 2007 06:58:42 -0500)

  NEW YORK (MarketWatch) -- Oculus Innovative Sciences Inc. priced its initial public offering at $8 a share, the bottom of its $8-$10 price range, for its stock market debut on Thursday. The maker of products to prevent infection in wounds raised about $24 million by offering 3 million shares with Roth Capital Markets.

• Oculus Innovative Sciences files $805 mln IPO

  (Mon, 03 Jul 2006 12:14:40 -0500)

  NEW YORK (MarketWatch) -- Oculus Innovative Sciences filed to raise up to $80.5 million in an initial public offering with underwriters A.G. Edwards , Jefferies & Co., First Albany Capital and C.E. Unterberg Towbin. The Petaluma, Calif. maker of products intended to prevent and eliminate infection in chronic and acute wounds plans to trade on the Nasdaq under the symbol "OCLS".

Only registered users can write comments.
Please login or register.

---